123 related articles for article (PubMed ID: 38666475)
1. Population Pharmacokinetics of Lamotrigine and Its N2-Glucuronide Metabolite in Chinese Patients with Epilepsy.
Yang H; Zhang D; Wei S; Zhao Z; Mei S
Ther Drug Monit; 2024 Apr; ():. PubMed ID: 38666475
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.
Xu S; Liu L; Chen Y; Liu M; Lu T; Wang H; Liu S; Zhao M; Zhao L
Eur J Clin Pharmacol; 2018 May; 74(5):583-591. PubMed ID: 29340733
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of topiramate in Chinese children with epilepsy.
Wei S; Li X; Zhang Q; Wu H; Wu Y; Zhao Z; Mei S; Feng W
Eur J Clin Pharmacol; 2023 Oct; 79(10):1401-1415. PubMed ID: 37597080
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Li X; Wei S; Wu H; Zhang Q; Zhao Z; Mei S; Feng W; Wu Y
Eur J Pediatr; 2023 Oct; 182(10):4509-4521. PubMed ID: 37493972
[TBL] [Abstract][Full Text] [Related]
5. Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.
Wang ML; Tao YY; Sun XY; Guo Y; Wang ZY; Cao YF; Zhao L
Pharmacol Res; 2021 Jul; 169():105610. PubMed ID: 33857625
[TBL] [Abstract][Full Text] [Related]
6. Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models.
Tauzin M; Tréluyer JM; Nabbout R; Billette de Villemeur T; Desguerre I; Aboura R; Gana I; Zheng Y; Benaboud S; Bouazza N; Chenevier-Gobeaux C; Freihuber C; Hirt D
J Clin Pharmacol; 2021 May; 61(5):677-687. PubMed ID: 33244764
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of
Shen X; Chen X; Lu J; Chen Q; Li W; Zhu J; He Y; Guo H; Xu C; Fan X
Front Pharmacol; 2022; 13():1037239. PubMed ID: 36506519
[No Abstract] [Full Text] [Related]
8. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
[TBL] [Abstract][Full Text] [Related]
9. Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy.
Chávez-Castillo CE; Medellín-Garibay SE; Milán-Segovia RDC; Rodríguez-Leyva I; Romano-Moreno S
J Pharm Sci; 2020 Sep; 109(9):2902-2908. PubMed ID: 32534880
[TBL] [Abstract][Full Text] [Related]
10. [Population pharmacokinetics of lamotrigine in Chinese children with epilepsy].
Zhang S; Wang L; Lu W
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Apr; 10(2):105-9. PubMed ID: 18433522
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of lamotrigine in Chinese children with epilepsy.
He DK; Wang L; Qin J; Zhang S; Lu W; Li L; Zhang JM; Bao WQ; Song XQ; Liu HT
Acta Pharmacol Sin; 2012 Nov; 33(11):1417-23. PubMed ID: 23103620
[TBL] [Abstract][Full Text] [Related]
12. Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.
Wang CB; Zhang YJ; Zhao MM; Zhao L
Int Immunopharmacol; 2023 Nov; 124(Pt A):110866. PubMed ID: 37678026
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model.
Gu X; Zhu M; Sheng C; Yu S; Peng Q; Ma M; Hu Y; Li Z; Jiao Z; Zhou B
Eur J Clin Pharmacol; 2021 Jul; 77(7):999-1009. PubMed ID: 33423079
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors.
Xu S; Chen Y; Zhao M; Guo Y; Wang Z; Zhao L
Eur J Pharm Sci; 2018 Sep; 122():170-178. PubMed ID: 29981400
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy.
Zhang ZB; Ji SM; Han Y; Zang LL; Wang YH; Lu W; Wang L; Wu Y
Eur J Clin Pharmacol; 2017 Apr; 73(4):445-453. PubMed ID: 28064355
[TBL] [Abstract][Full Text] [Related]
16. A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy.
Chen Y; Xu S; Wang Z; Zhao M; Wang H; Lu T; Zhao L
Ther Drug Monit; 2018 Dec; 40(6):730-737. PubMed ID: 30169477
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder.
Zang YN; Guo W; Niu MX; Bao S; Wang Q; Wang Y; Dong F; Li AN; Ruan CJ
Eur J Clin Pharmacol; 2022 Mar; 78(3):405-418. PubMed ID: 34854947
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data.
Takeuchi M; Yano I; Ito S; Sugimoto M; Yamamoto S; Yonezawa A; Ikeda A; Matsubara K
Ther Drug Monit; 2017 Apr; 39(2):124-131. PubMed ID: 28230619
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.
Milosheska D; Lorber B; Vovk T; Kastelic M; Dolžan V; Grabnar I
Br J Clin Pharmacol; 2016 Aug; 82(2):399-411. PubMed ID: 27096250
[TBL] [Abstract][Full Text] [Related]
20. Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level.
Huang S; Li L; Wang Z; Xiao T; Li X; Liu S; Zhang M; Lu H; Wen Y; Shang D
Drug Des Devel Ther; 2021; 15():3903-3913. PubMed ID: 34548782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
